Biocon Q1 PAT seen up 25% to Rs 88 cr

Revenues are seen going up by 28% to Rs 568 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) seen up by 21% at Rs 148 crore during the same period.

But, operating profit margin is likely to fall by 150 basis points at 26% YoY while the same seen up by 70 basis points QoQ.

On quarter-on-quarter basis, revenues are seen going down by 7% and profit after tax by 10%.
 
They expect growth to be led by biopharma and contract research and manufacturing services (CRAMS).

Biopharma would include growth from immunosuppresants / insulin / continued supplies of fidaxomicin. In case of CRAMS, company had mentioned seeing a good order inflow post Q4.

In the fourth quarter of FY12, all verticals contributed. Biopharma was up by 48% YoY to Rs 381 crore (which was 70% of sales), domestic branded formulation (11%) was up by 34% to Rs 65 crore and CRAMS rose by 33% (19% of sales) to Rs 120 crore.

Investors should watch out for licensing income. In the previous quarter, licensing income fell by 40% YoY Rs 46.3 crore.